ENTITY
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (GNP IN)

183
Analysis
Health Care • India
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company that develops, manufactures, and markets branded and generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on therapeutic areas including respiratory, dermatology, and oncology, with products such as Ryaltris, Winlevi, and Candid. It was founded in 1977 and is headquartered in Mumbai, India.
more
bullish•Greenland Hong Kong
•30 Jul 2020 08:54

Morning Views Asia: Glenmark Pharmaceuticals, Redco Properties

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region,...

Logo
354 Views
Share
•28 Jul 2020 17:09

Asia HY Trade Recommendations - July 2020 - Lucror Analytics

The Asia HY Trade Recommendations report for the month of July includes a summary of our recommendations, as well as our high-conviction ideas....

Logo
390 Views
Share
bearish•Greenland Hong Kong
•13 Jul 2020 08:53

Morning Views Asia: Alam Sutera Realty, Glenmark Pharmaceuticals

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region,...

Logo
313 Views
Share
•03 Jul 2020 15:58

Asia HY Monthly - Framework For Discerning Fraud In Asian Companies - Lucror Analytics

Following the recent string of high-profile fraud scandals, from Luckin Coffee in China to Wirecard in Germany, our In-Focus section this month...

Logo
489 Views
Share
•30 Jun 2020 17:12

Glenmark Pharmaceuticals - Earnings Flash - Q4 And FY 2019-20 Results - Lucror Analytics

Glenmark Pharmaceuticals’ Q4/19-20 results were better than expected, with a turnaround in profitability. The improved performance was attributed...

Logo
400 Views
Share
x